Biotech Intelligence Platform
Turn Global Biotech Signals, Into Strategic Intelligence
Top Signal This Week
The single most consequential move in biotech right now — curated by the INSILENS desk.
Novartis Acquires Myricx Bio — Next-Generation ADC Payload Platform
Novartis agreed to acquire Myricx Bio for up to $1.5B, including $1.1B upfront, adding a novel NMT-inhibitor ADC payload platform — a signal that big pharma is now paying premium value for payload architecture, not just late-stage clinical assets.
Biotech Signals. Structured for Decisions.
INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams.
Built for the people who move biotech forward
Different roles, different questions — INSILENS structures signals around how each team actually makes decisions.
Investors
Track financings, M&A activity, and emerging platforms early enough to act — not after the press release.
Executives
Monitor competitive movement across modalities and indications to inform pipeline and portfolio strategy.
Business Development
Surface partnership and licensing opportunities before they become competitive bidding wars.
Get the week's most important biotech signals — every Monday.
A curated digest of the deals, approvals, and technology shifts that matter, structured for fast decision-making.
